References
- Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother. 2003;51 Suppl 1(90001):13–20.
- Lewis T, Cook J. Fluoroquinolones and tendinopathy: a guide for athletes and sports clinicians and a systematic review of the literature. J Athl Train. 2014;49(3):422–427.
- Wise B, Peloquin C, Choi H, et al. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med. 2012;125(12):1228.e23–1228.e28.
- Kapoor KG, Hodge DO, St Sauver JL, et al. Oral fluoroquinolones and the incidence of rhegmatogenous retinal detachment and symptomatic retinal breaks: a population-based study. Ophthalmology. 2014;121(6):1269–1273.
- Ali AK. Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis. Ann Epidemiol. 2014;24(4):279–285.
- Cohen JS. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother. 2001;35(12):1540–1547.
- Kaur K, Fayad R, Saxena A, et al. Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network. J Community Support Oncol. 2016;14:54–65.
- Makaryus AN, Byrns K, Makaryus MN, et al. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant “clinical” event? South Med J. 2006;99(1):52–56.
- Alrwisan A, Antonelli PJ, Winterstein AG. Quinolone ear drops after tympanostomy tubes and the risk of eardrum perforation: a retrospective cohort study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017;64(8):1052–1058.
- Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open. 2015;5(11):e010077.
- Lee -C-C, Lee M-TG, Chen Y-S, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med. 2015;175(11):1839–1847.
- Food and Drug Administration. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes [Internet]. FDA; 2019 [cited 2022 May 12]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side.
- Food and Drug Administration. FDA briefing document - the benefits and risks of systemic fluoroquinolone antibacterial drugs for the treatment of Acute Bacterial Sinusitis (ABS), Acute Bacterial Exacerbation Of Chronic Bronchitis In Patients who Have Chronic Obstructive Pulmonary Disease (ABECB-COPD), and Uncomplicated Urinary Tract Infections (uUTI). [Internet]. 2015 [cited 2022 Mar 24]. Available from: https://web.archive.org/web/20160208032716/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM477657.pdf.
- Michalak K, Sobolewska-Włodarczyk A, Włodarczyk M, et al. Treatment of the fluoroquinolone-associated disability: the pathobiochemical implications. Oxid Med Cell Longev [Internet]. 2017 [cited 2020 Oct 1]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632915/.
- Marchant J. When antibiotics turn toxic. Nature. 2018;555(7697):431–433.
- Food and Drug Administration. FDA advisory committee 2013 report FQ toxicity. Internet]. 2013. Available from: No longer available online.
- Tsai W-C, Yang Y-M. Fluoroquinolone-associated tendinopathy. Chang Gung Med J. 2011;34(5):461–467.
- Guzzardi DG, Teng G, Kang S, et al. Induction of human aortic myofibroblast-mediated extracellular matrix dysregulation: a potential mechanism of fluoroquinolone-associated aortopathy. J Thorac Cardiovasc Surg. 2019;157(1):109–119.e2.
- Reviglio VE, Hakim MA, Song JK, et al. Effect of topical fluoroquinolones on the expression of matrix metalloproteinases in the cornea. BMC Ophthalmol. 2003;3(1):10.
- Badal S, Her YF, Maher LJ. Nonantibiotic effects of fluoroquinolones in mammalian cells. J Biol Chem. 2015;290(36):22287–22297.
- Jun C, Fang B. Current progress of fluoroquinolones-increased risk of aortic aneurysm and dissection. BMC Cardiovasc Disord. 2021;21(1):470.
- Tsai W-C, Hsu -C-C, Chen H-C, et al. Ciprofloxacin-mediated inhibition of tenocyte migration and down-regulation of focal adhesion kinase phosphorylation. Eur J Pharmacol. 2009 [cited 2022 Oct 14];607(1–3):23–26.
- Lawrence JW, Claire DC, Weissig V, et al. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Mol Pharmacol. 1996;50(5):1178–1188.
- Nadanaciva S, Dillman K, Gebhard DF, et al. High-content screening for compounds that affect mtDNA-encoded protein levels in eukaryotic cells. J Biomol Screen. 2010;15(8):937–948.
- Kalghatgi S, Spina CS, Costello JC, et al. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in mammalian cells. Sci Transl Med. 2013;5(192):192ra85.
- Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity.Chem Res Toxicol. 2008;21(1):172–188
- Hangas A, Aasumets K, Kekäläinen NJ, et al. Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of Topoisomerase 2. Nucleic Acids Res. 2018;46(18):9625–9636.
- LeMaire SA, Zhang L, Luo W, et al. Effect of ciprofloxacin on susceptibility to aortic dissection and rupture in mice. JAMA Surg. 2018;153(9):e181804.
- Divakaruni AS, Wiley SE, Rogers GW, et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci. 2013;110(14):5422–5427.
- Green MA, Halliwell RF. Selective antagonism of the GABA A receptor by ciprofloxacin and biphenylacetic acid. Br J Pharmacol. 1997;122(3):584–590.
- Halliwell RF, Davey PG, Lambert JJ. Antagonism of GABA A receptors by 4-quinolones. J Antimicrob Chemother. 1993 [cited 2020 Dec 20];31(4):457–462.
- Ilgin S, Can OD, Atli O, et al. Ciprofloxacin-induced neurotoxicity: evaluation of possible underlying mechanisms. Toxicol Mech Methods. 2015;25(5):374–381.
- Davey PG, Charter M, Kelly S, et al. Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. Antimicrob Agents Chemother. 1994;38(6):1356–1362.
- Schmuck G, Schürmann A, Schlüter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother. 1998 [cited 2020 Oct 1];42(7):1831–1836.
- De Sarro G, Nava F, Calapai G, et al. Effects of some excitatory amino acid antagonists and drugs enhancing gamma-aminobutyric acid neurotransmission on pefloxacin-induced seizures in DBA/2 mice. Antimicrob Agents Chemother. 1997;41(2):427–434.
- Moghimi A, Mollazadeh S, Rassouli FB, et al. The effect of ciprofloxacin injection on genetically absence prone (Wag/Rij) rat’s electroencephalogram characteristics. Basic Clin Neurosci. 2013 [cited 2020 Aug 16];4:31–35. Internet]. ;:. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202555/
- Pellegrini A, Giaretta D, Chemello R, et al. Feline generalized epilepsy induced by tranexamic acid (AMCA). Epilepsia. 1982;23(1):35–45.
- Yamaura A, Nakamura T, Makino H, et al. Cerebral complication of antifibrinolytic therapy in the treatment of ruptured intracranial aneurysm. animal experiment and a review of literature. Eur Neurol. 1980;19(2):77–84.
- Furtmüller R, Schlag MG, Berger M, et al. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a γ-aminobutyric acid a receptor antagonistic effect. J Pharmacol Exp Ther. 2002;301(1):168–173.
- Rye DB, Bliwise DL, Parker K, et al. Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABA A receptors. Sci Transl Med. 2012 [cited 2022 Mar 24];4(161). doi: 10.1126/scitranslmed.3004685.
- Robbins TW, Murphy ER. Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends Pharmacol Sci. 2006;27(3):141–148.
- Lynch DR, Rattelle A, Dong YN, et al. Chapter eleven - Anti-NMDA receptor encephalitis: clinical features and basic mechanisms. In: Pasternak GW, Coyle JT, editors. “Apprentices to Genius: A Tribute to Solomon H. Snyder”. Adv Pharmacol. Academic Press; 2018: 235–260 cited 2022 Mar 24]. Available from https://www.sciencedirect.com/science/article/pii/S1054358917300704
- Walker DL, Ressler KJ, K-T L, et al. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala Infusions of d-Cycloserine as assessed with fear-potentiated startle in Rats. J Neurosci. 2002;22(6):2343–2351.
- Monahan JB, Handelmann GE, Hood WF, et al. D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol Biochem Behav. 1989;34(3):649–653.
- Mehta A, Prabhakar M, Kumar P, et al. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol. 2013;698(1–3):6–18.
- van der Linden PD, MCJM S, Herings RMC, et al. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med. 2003;163(15):1801–1807.
- Food and Drug Administration. FDA’s center for drug evaluation and research. Application for cipro as a supplemental new drug application. (1) [Internet]. 2004 [cited 2022 May 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019537_S051_CIPRO.pdf.
- Madigan L. Illinois attorney general Lisa Madigan press release. Madigan, public citizen petition FDA for “Black Box” warning for certain popular antibiotics. Dated August 29, 2006, [Internet]. 2006. [cited 2022 May 23]. Available from: https://illinoisattorneygeneral.gov/pressroom/2006_08/20060829.html.
- Tanne JH. FDA adds “black box” warning label to fluoroquinolone antibiotics. BMJ. 2008 [cited 2022 Mar 24];337. Internet]. ;. Available from https://www.bmj.com/content/337/bmj.a816.
- Sasich LD, Wolfe SM. Petition to require a warning on all fluoroquinolone antibiotics [Internet]. Public Citiz. 1996 [cited 2022 May 17]. Available from: https://www.citizen.org/article/petition-to-require-a-warning-on-all-fluoroquinolone-antibiotics/.
- Food and Drug Administration. FDA/CDER response to Illinois attorney general’s office and public citizen health research group—partial approval/denial letter. (no longer available on the internet) [Internet]. 2006. [cited 2022 Apr 20]. Available from: http://www.regulations.gov/-!documentDetail;D=FDA-2006-P-0390-0005.
- Food and Drug Administration. FDA. Center for drug evaluation and research. Approval package for ciprofloxacin hydrochloride. Application number 19-537/S-068. [Internet]. 2008 [cited 2022 May 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/019537Orig1s068.pdf.
- Food and Drug Administration. FDA. Center for drug evaluation and research. Letter to ortho McNeil-Janssen pharmaceutical incorporated re/ proposed revised labeling. [Internet]. 2008. [cited 2022 May 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/020634s052,%20020635s057,021721s020ltr%20.pdf.
- Bayer P. Bayer health care pharmaceuticals. medication guide: CIPRO. Revised. [Internet]. 2008. [cited 2022 May 17]. Available from: https://www.fda.gov/media/73412/download.
- Janssen Ortho LLC. Medication Guide: LEVAQUIN. Revised [Internet]. 2008. [cited 2022 May 17]. Available from: https://www.fda.gov/media/75781/download.
- Arabyat RM, Raisch DW, McKoy JM, et al. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration’s adverse event reporting system. Expert Opin Drug Saf. 2015;14(11):1653–1660.
- Food and Drug Administration. CIPRO (ciprofloxacin hydrochloride) Revised. Whippany, NJ 07981: Bayer HealthCare Pharmaceuticals Inc; 2016b.
- The Canadian Press. Health Canada asks for tendon warning for some antibiotics | CBC News [Internet]. CBC. 2008. [cited 2022 May 23]. Available from: https://www.cbc.ca/news/science/health-canada-asks-for-tendon-warning-for-some-antibiotics-1.735102.
- Therapeutics Initiative. Drug safety advisories: a need for international coordination. [Internet]. 2020. [cited 2022 May 23]. Available from: https://www.ti.ubc.ca/2020/12/03/128-drug-safety-advisories-a-need-for-international-coordination/.
- Japan’s Pharmaceutical and Medical Devices Agency. Summary of investigation results: fluoroquinolones (oral and injectable dosage forms). [Internet]. 2019. [cited 2022 Mar 28]. Available from: https://www.pmda.go.jp/files/000227480.pdf.
- van der Linden PD, MCJM S, Herings RMC, et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ. 2002;324(7349):1306–1307.
- Medsafe. Quinolones- a tendency to rupture. Dated September 2012. [Internet]. 2012. [cited 2022 May 17]. Available from: https://www.medsafe.govt.nz/profs/PUArticles/QuinolonesSept2012.htm.
- Singer S. FDA’s office of safety and epidemiology post-marketing safety review: peripheral neuropathy associated with levofloxacin. ( no longer available on the internet). 2001
- Boxwell D, Cao K, Gilbert J, et al. Disabling peripheral neuropathy associated with system fluoroquinolone exposure. Internal pharmacovigilance review from the division of pharmacovigilance of the food and drug administration center for drug evaluation research’s office of surveillance and epidemiology. ( no longer available on the internet). 2013
- Food and Drug Administration. FDA’s center for drug evaluation and research. Application for Cipro as a supplemental new drug application. (2) [Internet]. 2004. [cited 2022 May 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019537_S053_CIPRO.pdf.
- Food and Drug Administration. FDA drug safety communications. FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. [Internet]. 2013. [cited 2022 May 23]. Available from: https://www.fda.gov/media/86575/download.
- European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products [Internet]. Eur. Med. Agency. 2018. [cited 2022 May 23]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products.
- European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics [Internet]. 2018. [cited 2021 Oct 29]. Available from: https://www.ema.europa.eu/en/documents/press-release/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone_en.pdf.
- Food and drug administration. LEVAQUIN© (levofloxacin) - label. Revised. [Internet]. 2013. [cited 2021 Aug 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020634s065,020635s071,021721s032lbl.pdf.
- HealthCanada. Summary safety review - Fluoroquinolones - Assessing the potential risk of persistent and disabling side effects [Internet]. 2016. [cited 2021 Oct 29]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-fluoroquinolones-assessing-potential-risk-persistent-disabling-effects.html.
- Australian Government Department of Health Therapeutic Goods. Update - fluoroquinolone antibiotics and adverse events [Internet]. Ther. Goods Adm. TGA. Australian Government Department of Health; 2020. [cited 2022 Mar 28]. Available from: https://www.tga.gov.au/publication-issue/update-fluoroquinolone-antibiotics-and-adverse-events.
- New Zealand’s Medicines Adverse Reaction Committee. Assessment of the potential risk of disabling and persistent musculoskeletal and nervous system reactions from the use of fluoroquinolones. [Internet]. 2017. [cited 2022 Mar 28]. Available from: https://www.medsafe.govt.nz/committees/marc/reports/172-Fluoroquinolones_Redacted.pdf.
- Golomb BA, Koslik HJ, Redd AJ. Fluoroquinolone-induced serious, persistent, multisymptom adverse effects. BMJ Case Rep. 2015;2015:bcr2015209821. DOI:10.1136/bcr-2015-209821.
- Food and Drug Administration. FDA updates warnings for fluoroquinolone antibiotics [Internet]. FDA. FDA; 2020. [cited 2022 Jun 6]. Available from: https://www.fda.gov/news-events/press-announcements/fda-updates-warnings-fluoroquinolone-antibiotics.
- Health Canada. Scientific advisory panel on anti-infective therapies (SAP-AIT) [Internet]. 2016. [cited 2022 May 12]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/scientific-expert-advisory-panels/anti-infective-therapies/announcement-meeting.html.
- Fresenius Kabi Canada Inc. Moxifloxacin injection. Product monograph. [Internet]. 2017. [cited 2022 Mar 24]. Available from: https://pdf.hres.ca/dpd_pm/00042564.PDF.
- Teva Canada. Cipro - Product monograph. [Internet]. 2017. [cited 2022 Mar 24]. Available from: https://pdf.hres.ca/dpd_pm/00042360.PDF.
- Apotex Inc. APO - Levofloxacin. product monograph. [Internet]. 2018. [cited 2022 Mar 24]. Available from: https://pdf.hres.ca/dpd_pm/00046102.PDF.
- Health Canada. FLUOROQUINOLONES - Risk of disabling and persistent serious adverse reactions - Recalls, advisories and safety alerts [Internet]. Government of Canada, Health Canada, Marketed health products; 2021. [cited 2022 May 12]. Available from: https://recalls-rappels.canada.ca/en/alert-recall/fluoroquinolones-risk-disabling-and-persistent-serious-adverse-reactions.
- Health Canada. Information Update - Fluoroquinolone antibiotics may, in rare cases, cause persistent disabling side effects - Recalls, advisories and safety alerts [Internet]. Government of Canada, Health Canada, Communications and Public Affairs Branch; 2021. [cited 2022 May 12]. Available from: https://recalls-rappels.canada.ca/en/alert-recall/information-update-fluoroquinolone-antibiotics-may-rare-cases-cause-persistent.
- European Medicines Agency. Referral procedures [Internet]. Eur. Med. Agency. 2018. [cited 2022 Mar 28]. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/referral-procedures.
- PRAC. PRAC recommendations on signals - Adopted at the 3-6 September 2018 PRAC meeting [Internet]. 2018. [cited 2021 Oct 28]. Available from: https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-september-2018-prac-meeting_en-0.pdf.
- Medicines Adverse Reactions Committee. FQs and aortic aneurysm/dissection. [Internet]. 2019. [cited 2022 May 17]. Available from: https://www.medsafe.govt.nz/committees/marc/reports/178-3.2.3FluoroquinolonesAndAorticAneurysm.pdf.
- Japanese Ministry of Health Labour and Welfare. Revisions of Precautions (Ciprofloxacin, Levofloxacin, and Moxifloxacin) [Internet]. 2019. [cited 2022 Mar 28]. Available from: https://www.pmda.go.jp/files/000227472.pdf.
- Food and Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients [Internet]. FDA. FDA; 2019. [cited 2021 Oct 28]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics.
- Singh S, Nautiyal A. Aortic dissection and aortic aneurysms associated with fluoroquinolones: a systematic review and meta-analysis. Am J Med. 2017;130(12):1449–1457.e9.
- Lee -C-C, Lee M-TG, Hsieh R, et al. Oral fluoroquinolone and the risk of aortic dissection. J Am Coll Cardiol. 2018;72(12):1369–1378.
- Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:k678.
- MARC Committee. MARC committee report on FQs. Dated June 13. [Internet]. 2019. [cited 2022 May 17]. Available from: https://www.medsafe.govt.nz/committees/marc/reports/178-3.2.3FluoroquinolonesAndAorticAneurysm.pdf.
- Food and Drug Administration. AVELOX (moxifloxacin hydrochloride). Whippany, NJ 07981: Bayer HealthCare Pharmaceuticals Inc; 2016a.
- Health Canada. Summary Safety Review - Fluoroquinolones - Assessing the potential risk of aneurysm (a balloon-like bulge) and dissection (a separation or tear in the layers of the wall) of the aorta (a major blood vessel) [Internet]. 2016. [cited 2021 Oct 29]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-fluoroquinolones-assessing-potential-risk-persistent-disabling-effects.html.
- Health Science Authority. Fluoroquinolones and risk of aortic aneurysm and dissection [Internet]. HSA. 2019. [cited 2022 Mar 24]. Available from: https://www.hsa.gov.sg/announcements/safety-alert/fluoroquinolones-and-risk-of-aortic-aneurysm-and-dissection.
- Electronic Medicines Compendium. Levofloxacin 500mg Film-coated tablets - Summary of Product characteristics. Revised [Internet]. 2015. [cited 2022 Mar 24]. Available from: https://www.medicines.org.uk/emc/product/4625/smpc#gref.
- Sommet A, Bénévent J, Rousseau V, et al. What fluoroquinolones have the highest risk of aortic aneurysm? A case/non-case study in VigiBase®. J Gen Intern Med. 2019 [cited 2021 Oct 28];34(4):502–503.
- Australian Government Department of Health Therapeutic Goods. Fluoroquinolone antibiotics and risk of aortic aneurysm/dissection [Internet]. Ther. Goods Adm. TGA. Australian Government Department of Health; 2019. [cited 2021 Oct 29]. Available from: https://www.tga.gov.au/publication-issue/fluoroquinolone-antibiotics-and-risk-aortic-aneurysmdissection.
- European Medicines Agency. Systemic and inhaled fluoroquinolones: risk of heart valve regurgitation/incompetence [Internet]. Eur. Med. Agency. 2020. [cited 2022 Jun 6]. Available from: https://www.ema.europa.eu/en/medicines/dhpc/systemic-inhaled-fluoroquinolones-risk-heart-valve-regurgitationincompetence.
- Medicines and Health Regulatory Authority. Drug safety update: FQ associated risk of heart valve regurgitation/incompetence. [Internet]. GOV.UK. 2018. [cited 2022 May 17]. Available from: https://www.gov.uk/drug-safety-update.
- Health Science Authority. Risk of heart valve regurgitation with fluoroquinolones [Internet]. 2021. [cited 2022 Jun 6]. Available from: https://www.hsa.gov.sg/announcements/safety-alert/risk-of-heart-valve-regurgitation-with-fluoroquinolones.
- British Generic Manufacturers Association. Direct healthcare professional communication on systemic and inhaled fluoroquinolones: risk of heart valve regurgitation/incompetence. [Internet]. 2020. [cited 2022 May 17]. Available from: https://assets.publishing.service.gov.uk/media/5ff59241e90e0776aa14132a/Fluoroquinolones_DHCP_09-12.pdf.
- Etminan M, Sodhi M, Ganjizadeh-Zavareh S, et al. Oral fluoroquinolones and risk of mitral and aortic regurgitation. J Am Coll Cardiol. 2019;74(11):1444–1450.
- Bennett A, Qureshi Z, Bennett C. A novel genetic marker has been identified in patients with fluoroquinolone-associated neuropsychiatric toxicity: preliminary findings. Abstr 55 2017 AVAHO Meet [Internet]. [cited 2021 Oct 28]; Available from: https://www.mdedge.com/fedprac/avaho/article/146822/novel-genetic-marker-has-been-identified-patients-fluoroquinolone.